Welcome to our Cannabis Earnings series where we break down the latest earnings to help you focus on the most important topics.
Introduction
MediPharm Labs (MEDIF) once again demonstrated its ability to deliver as it announced a strong quarter of growth and profitability. We think the company is single-handedly proving the viability of the extraction business model, and we expect the upcoming legalization of edibles and concentrates in Canada as the biggest near-term tailwind for the stock.
(All amounts in C$)
2019 Q2 Review
MediPharm reported second-quarter results that showed continuous expansion of the business